Understanding POTS: Insights from Dr. Stavros Stavrakis on Diagnosis and Treatment

Insights from Dr. Stavros Stavrakis on POTS and Vagus Nerve Stimulation

Introduction to POTS and New Therapeutic Approaches

Dr. Stavros Stavrakis recently discussed his research paper titled “Noninvasive Vagus Nerve Stimulation in Postural Tachycardia Syndrome: A Randomized Clinical Trial.” This study presents a promising new treatment for individuals suffering from postural tachycardia syndrome (POTS). Researchers in Oklahoma propose the use of a compact, portable neuromodulation device designed to alleviate the challenging symptoms associated with POTS.

POTS patients often experience difficulties regulating heart rate, particularly a notable increase when transitioning to an upright position, along with issues related to blood pressure, respiration, and heightened levels of adrenaline. The therapeutic approach involves transcutaneous electrical stimulation of the vagus nerve, utilizing a TENS machine to impact these physiological functions.

Mechanism of Action of the Device

The device delivers targeted micropulses of electrical current aimed at modulating the autonomic nervous system. The vagus nerve, extending from the brain through the heart and lungs to the intestines, plays a crucial role in regulating heart rate, blood vessel constriction, digestion, respiration, and immune responses. Stimulating the vagus nerve may help alleviate symptoms such as dizziness, fainting, and fatigue.

Interview with Dr. Stavros Stavrakis

We had the opportunity to speak with Dr. Stavrakis, a clinical cardiac electrophysiologist and Associate Professor of Medicine at the University of Oklahoma Health Sciences Center. His research primarily focuses on cardiology, including atrial fibrillation, arrhythmias, and POTS.

Development of the Vagus Nerve Stimulation Device

*Medical News Bulletin*: How did the idea for the device come about, and is it the first of its kind?
*Dr. Stavrakis*: The concept of tragus stimulation originated from our team; however, the device itself is commercially available, specifically the Parasym™ TENS machine. Currently, it is not available in the United States but can be found in Europe. We observed various beneficial effects of this device on cardiac health, including inflammation suppression, reduced arrhythmias, and improved heart structure and function. Given the multifaceted nature of POTS, we hypothesized that using this device could mitigate the increase in heart rate that occurs upon standing. This intervention targets adrenergic activity, which is linked to elevated adrenaline levels. Our initial tests in animals demonstrated a reduction in heart rate elevation and inflammation, leading us to advance into human trials.

Findings on POTS Causes

*Medical News Bulletin*: What do your study results suggest about the underlying causes of POTS?
*Dr. Stavrakis*: Our findings suggest that POTS is a multifactorial condition, with increased adrenaline being a significant factor. However, there’s still much to learn regarding its pathophysiology. A key observation was the decrease in antibodies following device stimulation, which is a critical finding. The therapeutic potential of this device remains to be fully determined, and we are currently categorizing patients into larger subgroups for further analysis.

Safety and Longevity of the Device

*Medical News Bulletin*: Is there anyone that shouldn’t use this device, for example, those with pacemakers?
*Dr. Stavrakis*: There are no restrictions; the device’s output is minimal and has shown to benefit individuals with atrial fibrillation. We previously conducted a study published in 2020 titled “TREAT AF (Transcutaneous Electrical Vagus Nerve Stimulation to Suppress Atrial Fibrillation): A Randomized Clinical Trial.”

*Medical News Bulletin*: What is the longevity of the device?
*Dr. Stavrakis*: The device can be effective for at least 6 months to a year. Prior studies indicate a sustained effect even after stimulation ceases, meaning daily use is not necessary, although further testing is required to confirm this.

Future Directions

*Medical News Bulletin*: What are the next steps for you and your team following the findings of this study?
*Dr. Stavrakis*: Our goal is to personalize this therapy and identify which patients would benefit most from using the device.

*Medical News Bulletin*: How widespread do you envision the device being used in the general public?
*Dr. Stavrakis*: If we can effectively identify suitable patients for the device, it could become a primary treatment option.

The Role of Technology in Future Treatments

*Medical News Bulletin*: With the rise of artificial intelligence and machine learning, do you foresee these technologies aiding in predicting which patients might respond best to treatments like noninvasive vagus nerve stimulation?
*Dr. Stavrakis*: I envision the development of an earpod capable of measuring physiological biomarkers and initiating treatment as needed. This biomarker data could then be processed through an AI algorithm to provide actionable insights. I anticipate this advancement within the next 5 to 10 years.

We extend our gratitude to Dr. Stavrakis for sharing his insights and expertise with us.